At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 432 enrolled
Drug / intervention
Roflumilast Foam 0.3% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized tRial Employing topiCal roflumilasT Foam to Treat Scalp Psoriasis (ARRECTOR)
In Brief
A Phase 3 clinical trial evaluating Roflumilast Foam 0.3% and Vehicle Foam for Scalp Psoriasis. Completed, enrolled 432 participants across 49 sites in 2 countries.
Detailed Summary
This was a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-154) 0.3% foam vs vehicle foam applied once daily (qd) for 8 weeks by participants with plaque psoriasis of the scalp and body.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScalp Psoriasis
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartAug 2021
First PostedAug 2021
Primary CompletionJun 2022
TodayJul 2026
First PostedAug 31, 2021
Enrollment StartAug 24, 2021
Primary CompletionJun 3, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.8 years ago
Interventions
Roflumilast Foam 0.3%drug
Roflumilast foam 0.3%
Vehicle Foamdrug
Vehicle foam matched to roflumilast 0.3% foam.